GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Price-to-Tangible-Book

Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Price-to-Tangible-Book : 2.03 (As of May. 12, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-12), Aurinia Pharmaceuticals's share price is $5.02. Aurinia Pharmaceuticals's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $2.47. Hence, Aurinia Pharmaceuticals's Price to Tangible Book Ratio of today is 2.03.

The historical rank and industry rank for Aurinia Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

AUPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.54   Med: 4.62   Max: 29.78
Current: 2.03

During the past 13 years, Aurinia Pharmaceuticals's highest Price to Tangible Book Ratio was 29.78. The lowest was 1.54. And the median was 4.62.

AUPH's Price-to-Tangible-Book is ranked better than
63.06% of 1221 companies
in the Biotechnology industry
Industry Median: 2.7 vs AUPH: 2.03

A closely related ratio is called PB Ratio. As of today, Aurinia Pharmaceuticals's share price is $5.02. Aurinia Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2024 was $2.50. Hence, Aurinia Pharmaceuticals's P/B Ratio of today is 2.01.


Aurinia Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Aurinia Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Price-to-Tangible-Book Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.82 4.40 6.88 1.54 3.47

Aurinia Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.08 3.59 2.89 3.47 2.03

Competitive Comparison of Aurinia Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Price-to-Tangible-Book falls into.



Aurinia Pharmaceuticals Price-to-Tangible-Book Calculation

Aurinia Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=5.02/2.469
=2.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Aurinia Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
Executives
Robert T Foster director C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
R. Hector Mackay-dunn director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w. director #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Jill Leversage director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Daniel Billen director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Brinda Balakrishnan director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Peter Greenleaf director, officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Joseph M Miller officer: Chief Financial Officer C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Stephen P. Robertson officer: EVP, General Counsel #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Milne George M Jr director
Matthew Maxwell Donley officer: Ex VP, Intern'l Operations 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Scott Michael Habig officer: Chief Commercial Officer #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8

Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Headlines

From GuruFocus

Aurinia Announces 2023 Annual General Meeting Results

By Business Wire Business Wire 05-17-2023